Predictive QSAR modeling of HIV reverse transcriptase inhibitor TIBO derivatives.

Comparative quantitative structure-activity relationship (QSAR) studies have been carried out on tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepine (TIBO) derivatives as reverse transcriptase inhibitors (n=70) using topological, structural, physicochemical, electronic and spatial descriptors. The data set was divided into training and test sets using a cluster-based method. Linear models were developed using multiple regression (with stepwise regression, factor analysis and genetic function approximation (GFA) as variable selection tools) and partial least squares (PLS) and combination of factor analysis and partial least squares (FA-PLS). Genetic function approximation (spline) and artificial neural networks (ANN) were used for the development of non-linear models. Using topological and structural descriptors, the best equation was obtained from GFA (spline) based on internal validation (Q(2)=0.737), but the model with the best external validation characteristics was obtained with FA-PLS (R(pred)(2)=0.707). When structural, physicochemical, electronic and spatial descriptors were used, the best Q(2) (0.740) value was obtained from GFA (spline) whereas PLS provided the best R(pred)(2) (0.784) value. When all descriptors were used in combination, the best R(pred)(2) (0.760) value and the best Q(2) (0.800) value were obtained from ANN and GFA (spline), respectively. The majority of the models satisfied the criteria of external validation recommended by Golbraikh and Tropsha (2002) and the criteria of modified r(2) (r(m)(2)) values of the test set for external validation as suggested by Roy and Roy (2008). In order to further validate selected models, an external set of 10 TIBO derivatives, which fall within the applicability domain of the models and are not shared with the compounds of the present data set, was taken from a different source, and reverse transcriptase inhibitory activity of these compounds was predicted. Acceptable values of squared correlation coefficients between the observed and predicted values of the external set compounds were obtained from the selected models suggesting true predictive potential of the models.

[1]  Rainer Franke,et al.  Theoretical drug design methods , 1984 .

[2]  K. Roy,et al.  Classical QSAR Modeling of Anti‐HIV 2,3‐Diaryl‐1,3‐thiazolidin‐4‐ones , 2005 .

[3]  K. Roy,et al.  QSAR by LFER model of cytotoxicity data of anti-HIV 5-phenyl-1-phenylamino-1H-imidazole derivatives using principal component factor analysis and genetic function approximation. , 2005, Bioorganic & medicinal chemistry.

[4]  Zhigang Zhou,et al.  CoMFA 3D-QSAR Analysis of HIV-1 RT Nonnucleoside Inhibitors, TIBO Derivatives Based on Docking Conformation and Alignment , 2004, J. Chem. Inf. Model..

[5]  Supa Hannongbua,et al.  Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatised HIV-1 reverse transcriptase inhibitors , 1999, J. Comput. Aided Mol. Des..

[6]  K. Roy,et al.  Classical QSAR Modeling of HIV‐1 Reverse Transcriptase Inhibitor 2‐Amino‐6‐arylsulfonylbenzonitriles and Congeners , 2004 .

[7]  J N Weinstein,et al.  Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies. , 2001, Journal of medicinal chemistry.

[8]  F. Uckun,et al.  Structure-Based Design of Non-Nucleoside Reverse Transcriptase Inhibitors of Drug-Resistant Human Immunodeficiency Virus , 1999, Antiviral chemistry & chemotherapy.

[9]  Han van de Waterbeemd,et al.  Chemometric methods in molecular design , 1995 .

[10]  Cristina Tintori,et al.  Novel Virtual Screening Protocol Based on the Combined Use of Molecular Modeling and Electron-Ion Interaction Potential Techniques To Design HIV-1 Integrase Inhibitors , 2007, J. Chem. Inf. Model..

[11]  Rajni Garg,et al.  From SAR to comparative QSAR: role of hydrophobicity in the design of 4-hydroxy-5,6-dihydropyran-2-ones HIV-1 protease inhibitors. , 2005, Bioorganic & medicinal chemistry.

[12]  Kunal Roy,et al.  On Selection of Training and Test Sets for the Development of Predictive QSAR models , 2006 .

[13]  K. Roy,et al.  Comparative QSAR modeling of CCR5 receptor binding affinity of substituted 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas. , 2006, Bioorganic & medicinal chemistry letters.

[14]  P. Roy,et al.  On Some Aspects of Variable Selection for Partial Least Squares Regression Models , 2008 .

[15]  Johann Gasteiger,et al.  Neural networks in chemistry and drug design , 1999 .

[16]  Anton J. Hopfinger,et al.  Application of Genetic Function Approximation to Quantitative Structure-Activity Relationships and Quantitative Structure-Property Relationships , 1994, J. Chem. Inf. Comput. Sci..

[17]  Kunal Roy,et al.  Classical QSAR Modeling of CCR5 Receptor Binding Affinity of Substituted Benzylpyrazoles , 2004 .

[18]  A. Fraser,et al.  Computer models in genetics , 1970 .

[19]  G. W. Snedecor.  Statistical Methods , 1964 .

[20]  R. Darlington,et al.  Regression and Linear Models , 1990 .

[21]  Kunal Roy,et al.  QSAR by LFER model of HIV protease inhibitor mannitol derivatives using FA-MLR, PCRA, and PLS techniques. , 2006, Bioorganic & medicinal chemistry.

[22]  Kunal Roy,et al.  QSAR Analyses of 3-(4-Benzylpiperidin-1-yl)-N-phenylpropylamine Derivatives as Potent CCR5 Antagonists , 2005, J. Chem. Inf. Model..

[23]  Brian Everitt,et al.  Cluster analysis , 1974 .

[24]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[25]  Jan Balzarini,et al.  Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents. , 2002, Journal of medicinal chemistry.

[26]  K. Roy,et al.  QSAR modeling of anti-HIV activities of alkenyldiarylmethanes using topological and physicochemical descriptors. , 2003, Drug design and discovery.

[27]  Kunal Roy,et al.  QSAR modeling of HIV-1 reverse transcriptase inhibitor 2-amino-6-arylsulfonylbenzonitriles and congeners using molecular connectivity and E-state parameters. , 2004, Bioorganic & medicinal chemistry.

[28]  Rajarshi Guha,et al.  Determining the Validity of a QSAR Model - A Classification Approach , 2005, J. Chem. Inf. Model..

[29]  E. Kellenberger,et al.  Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. , 2007, Journal of medicinal chemistry.

[30]  Jarmo Huuskonen.  QSAR Modeling with the Electrotopological State: TIBO Derivatives , 2001, J. Chem. Inf. Comput. Sci..

[31]  Yenamandra S Prabhakar,et al.  2-(Aryl)-3-furan-2-ylmethyl-thiazolidin-4-ones as selective HIV-RT inhibitors. , 2005, Bioorganic & medicinal chemistry.

[32]  J. Buolamwini,et al.  CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. , 2002, Journal of medicinal chemistry.